Cancer clinical trials in the region Bourgogne-Franche-Comté

209 currently recruiting clinical trials
Region Bourgogne-Franche-Comté

Phase 3 Head and neck cancer #NCT04747054
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx Other
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 20) CPS Positive (X >= 20)
20 recruiting sites
UNICANCER
Phase 3 Head and neck cancer #NCT06256588 #2023-508613-17-00
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Radiochemotherapy
Required CPS scores
CPS Positive (1 <= X < 20) CPS Positive (X >= 20)
Excluded previous treatments at advanced or metastatic stage
Surgery Immunotherapy Targeted therapy Radiotherapy
7 recruiting sites
GlaxoSmithKline
Phase 3 Breast cancer #NCT06382948
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ESR
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded genetic anomalies
ESR
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy
8 recruiting sites
MedSIR
Phase 3 Lung cancer #NCT06623422 #2023-506327-29-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK EGFR
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
8 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Colon cancer Rectal cancer #NCT06252649 #2022-502352-31-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
16 recruiting sites
Amgen
Phase 3 Breast cancer #NCT06492616 #2024-515445-42-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Excluded previous treatments at localized stage
Hormone therapy
22 recruiting sites
Stemline Therapeutics, Inc.
Phase 3 Colon cancer Rectal cancer #NCT06107920 #2024-516456-17-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Chemotherapy Radiotherapy
28 recruiting sites
Hôpital universitaire de Rouen
Phase 3 Breast cancer #NCT06435429
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Jazz Pharmaceuticals
Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06072781
Required histologic types
Epithelial ovarian cancer
Required histologic sub types
Serous low grade carcinoma (LGSOC)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Verastem
Phase 3 Lung cancer #NCT06345729 #2023-507776-42-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Merck Sharp & Dohme LLC